R&D News | pharmaphorum

News

J&J reels in bispecific specialist Proteologix in $850m deal

Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, inc

News

TIGIT developer iTeos raises $120m, and other financings

Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for L

News

Roche trumpets potential ‘best-in-class’ obesity drug

Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced las

News

GSK, UK govt put £130m into antimicrobial resistance fight

GSK has become the first founding partner of the new Fleming Initiative, which aims to tackle the rising threat of antimicrobial resistance (AMR) and is also backed by the

News

Updated BIOSECURE Act draft clears House committee

Legislation that would restrict US organisations from contracting with some Chinese biotech providers has been passed by a House of Representatives committee, moving close

News

Uniquity Bio emerges with $300m for MSD immunology drug

New start-up Uniquity Bio arrived on the scene today with $300 million in funding from Blackstone Life Sciences and a clinical-stage inflammation and immunology drug licen

J&J reels in bispecific specialist Proteologix in $850m deal

TIGIT developer iTeos raises $120m, and other financings

Roche trumpets potential ‘best-in-class’ obesity drug

GSK, UK govt put £130m into antimicrobial resistance fight

Updated BIOSECURE Act draft clears House committee

Uniquity Bio emerges with $300m for MSD immunology drug

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks